Suchergebnisse - "d'Ettorre, Gabriella"

PubPharm (14)

1

Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors : A retrospective cohort study

enthalten in: Journal of medical virology | 2023

von Lagi, F. | Giacomelli, A. | Borghi, V. | +12

2

Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy : Much More Than a Positive Finding

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2021

von Ciccullo, A. | Borghi, V. | Giacomelli, A. | +13

3

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients : Data from real-life ODOACRE cohort

enthalten in: HIV medicine | 2021

von Fabbiani, M. | Rossetti, B. | Ciccullo, A. | +31

4

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

enthalten in: International journal of antimicrobial agents | 2019

von Baldin, G. | Ciccullo, A. | Rusconi, S. | +11

5

A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)

enthalten in: PloS one | 2019

von Mussini, C. | Roncaglia, E. | Borghi, V. | +15

6

A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients

enthalten in: Antiviral therapy | 2019

von Ciccullo, A. | Baldin, G. | Capetti, A. | +11

7

Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients : 96 week outcomes of a randomized trial

enthalten in: The Journal of antimicrobial chemotherapy | 2018

von Fabbiani, M. | Gagliardini, R. | Ciccarelli, N. | +120

8

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Lombardi, F. | Belmonti, S. | Quiros-Roldan, E. | +9

9

Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients : 48 week results from a randomized trial (ATLAS-M)

enthalten in: The Journal of antimicrobial chemotherapy | 2017

von Di Giambenedetto, S. | Fabbiani, M. | Quiros Roldan, E. | +19

10

Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification : a multicenter observational study

enthalten in: BMC infectious diseases | 2016

von Latini, A. | Fabbiani, M. | Borghi, V. | +11